CBS 2019
CBSMD教育中心
首页
CBS 2019
关于CBS
会议通知
会议组织
主办单位
南京市心血管病医院
亚洲分叉病变俱乐部
南京医科大学附属南京医院
南京市第一医院医学发展医疗救助基金会
协办单位
中华医学会心血管病学分会
国家卫生健康委能力建设和继续教育心血管病学专家委员会（CBCEC）
美国心血管造影和介入学会
亚洲心脏学会
北京合众关爱心脏健康基金会
联系我们
境内代表注册管理:
彭红娟 ：
+86-13913895477
徐海梅 ：+86-13914736846
cbsnj@cbsmd.cn
境外代表注册管理:
林玲 ： +86 (25) 52271398
+86-13951884596
cbs@cbsmd.cn
病例征集管理:
赵莹莹 ：+86-13815408517
sub@cbsmd.cn
地址：
江苏省南京市秦淮区长乐路68号，南京市心血管病医院9号楼905区心内科办公室
210006
主席团
主席团
大会主席
联合主席
教育中心
教育中心
• 线上教育 （ 注册后可使用个人定义界面搜集科研图书馆文献、下载教育资源、参与在线病例讨论。）
• 教育资源
• 科研动态
科研图书馆
科研图书馆
科研文章
> 急性冠脉综合征
> 动脉粥样硬化性心血管疾病
> 分叉支架
> 心脏肿瘤科
> 充血性心力衰竭
> 双重抗血小板治疗持续时间
> 药物涂层球囊
> 血流储备分数
> 血管内超声指导
> 光学相关断层扫描
> 肺动脉高压
> 旋磨术
> 血流动力学与动脉粥样硬化
> 左主干支架
> 经导管主动脉瓣置换
> 经皮左心耳封堵
> 二尖瓣/三尖瓣瓣膜
> 推荐文献
荐读文献
Management of Acute Myocardial Infarction During the COVID-19 Pandemic
CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic
ACC临床简报:新型冠状病毒对心脏的影响(2019-nCoV)
SCAI Expert Consensus Statement Update on Best Practices for Transradial Angiography and Intervention
Clinical Trial | By DR Holmes, VY Reddy, PROTECT AF Investigators et al.
BACKGROUND - In patients with non-valvular atrial fibrillation, embolic stroke is thought to be associated with left atrial appendage (LAA) thrombi. We assessed the efficacy and safety of percutaneous closure of the LAA for prevention of stroke compared with warfarin treatment in patients with atrial fibrillation. METHODS - Adult patients with non-valvular atrial fibrillation were eligible for inc...
Clinical Trial | By VY Reddy, SK Doshi, PROTECT AF Investigators et al.
Contrast-Associated Acute Kidney Injury and Serious Adverse Outcomes Following Angiography
Original Research | By SD Weisbord, PM Palevsky, the PRESERVE Trial Investigators et al.
BACKGROUND - Contrast-associated acute kidney injury (CA-AKI) associates with an increased relative risk for serious adverse outcomes. However, the magnitude of this risk and the incidence of clinically significant CA-AKI derived from analyses of large cohorts with prospective assessment of CA-AKI and subsequent outcomes are unknown. OBJECTIVES - This study sought to char...
2-Year Outcomes After Stenting of Lipid-Rich and Nonrich Coronary Plaques
Original Research | By MHwa Yamamoto, A Maehara, GW Stone et al.
BACKGROUND- Autopsy studies suggest that implanting stents in lipid-rich plaque (LRP) may be associated with adverse outcomes. OBJECTIVES- The purpose of this study was to evaluate the association between LRP detected by near-infrared spectroscopy (NIRS) and clinical outcomes in patients with coronary artery disease treated with contemporary drug-eluting stents. METHODS...
Original Research | By G Mendieta, S Ben-Aicha, M Gutiérrez et al.
BACKGROUND - Beyond lipid-lowering, statins exert cardioprotective effects. High-dose statin treatment seems to reduce cardiovascular complications in high-risk patients. The ideal timing and administration regime remain unknown. OBJECTIVES - This study compared the cardioprotective effects of intravenous statin administration during myocardial infarction (MI) with oral administratio...
Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk
Original Research | By S Windecker, A Latib, the ONYX ONE Investigators et al.
BACKGROUND - Polymer-free drug-coated stents provide superior clinical outcomes to bare-metal stents in patients at high bleeding risk who undergo percutaneous coronary intervention (PCI) and are treated with 1 month of dual antiplatelet therapy. Data on the use of polymer-based drug-eluting stents, as compared with polymer-free drug-coated stents, in such patients are limited. METHODS - In an interna...
Clinical Trial | By YJ Youn, J-W Lee, J Yoon et al.
BACKGROUND - There is limited data comparing the Xience everolimus-eluting stent (EES) and the Resolute zotarolimus-eluting stent (ZES) with the BioMatrix biolimus-eluting stent (BES). METHODS - This open-label, randomized, noninferiority trial enrolled all-comer patients to be randomly treated with either BES, EES, or ZES in a 1:1:1 ratio in 15 centers across South Korea. The primar...
Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study
Review Article | By NL Pereira, CS Rihal, DYF So et al.
Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional protein, and carriers of these loss-of-function alleles when treated with clopidogrel have significantly reduced clopidogrel active metabolite levels and high on-treatment platelet reactivity resulting in increased risk of major adverse cardiovascular events, especially after percutaneous ...
English
CBS 2019
CBS 2019 主席团
教育中心
科研动态
